Clinical Trials

Triple Negative Breast Neoplasms

NCT05177796 2024-10-24

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2 Withdrawn

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02689427 2024-09-19

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06387628 2024-08-02

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Phase 2 Recruiting

74 enrolled

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT02488967 2024-06-03

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

782 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03719326 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

35 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT02672475 2023-11-22

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

29 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04734262 2023-11-18

SPARK

98 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

9 enrolled 17 charts

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03193853 2023-08-07

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

12 enrolled 11 charts

Triple Negative Breast Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

65 enrolled

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

62 enrolled 7 charts

Phase EARLY_PHASE1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04249167 2023-01-06

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

BreastGastrointestinalGynecologic

Triple Negative Breast Neoplasms

NCT02762981 2022-12-06

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Phase 1/2 Completed

85 enrolled 24 charts

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02474173 2022-11-04

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Phase 1 Terminated

31 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT04676997 2020-12-21

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

20 enrolled

Triple Negative Breast Neoplasms

NCT00733408 2018-12-04

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

59 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01009983 2018-07-06

Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Terminated

14 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01276496 2016-03-15

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

13 enrolled

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01238133 2015-09-04

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Phase 1 Terminated

14 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01281150 2015-05-25

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

22 enrolled

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00479674 2015-02-18

ABC

41 enrolled 8 charts